Unique ID issued by UMIN | UMIN000053093 |
---|---|
Receipt number | R000060587 |
Scientific Title | A descriptive observational research for the treatment pattern in patients with Lupus Nephritis using Japanese claim database |
Date of disclosure of the study information | 2023/12/14 |
Last modified on | 2024/12/04 16:27:38 |
A descriptive observational research for the treatment pattern in patients with Lupus Nephritis using Japanese claim database
Observational research in patients with lupus nephritis using claim database
A descriptive observational research for the treatment pattern in patients with Lupus Nephritis using Japanese claim database
Observational research in patients with lupus nephritis using claim database
Japan |
Lupus nephritis
Nephrology | Clinical immunology |
Others
NO
To describe the oral glucocorticoid (GC) dose changes in patients with lupus nephritis who are introduced the induction treatment
Others
Proportion of patients on oral GC 5 mg/day or less (prednisolone equivalent) after 540 days from the Index Date
Proportion of patients on oral GC 5 mg/day or less (prednisolone equivalent) after 540 days from the Index Date
Observational
Not applicable |
Not applicable |
Male and Female
LN Patients treated with induction treatment and meet all of the following (1) to (8):
(1) Diagnosed with lupus nephritis (defined as 7100007 excluding suspected cases in a disease code) for at least 2 months between May 2016 and March 2023
(2) Prescription of oral GC or steroid pulse therapy at the dose of 20 mg/day or more with a disease code 7100007 (lupus nephritis) issued in the same month
(3) Observable for at least 90 days prior to Index Date
(4) Observable for at least 540 days after the Index Date
(5) No oral GC or steroid pulse therapy 20 mg/day or more for 90 days prior to the Index Date
(6) Urinalysis was performed and the month in which a disease code 7100007 excluding suspected cases was given at least 2 months within 360 days after the Index Date
(7) Anti-DNA antibody test was performed and the month in which a disease code 7100007 excluding suspected cases was given at least 2 months within 360 days after the Index Date
(8) Complement Blood test was performed and the month in which a disease code 7100007 excluding suspected cases was given at least 2 months within 360 days after the Index Date
Dose of oral GC and steroid pulse are converted equivalent to prednisolone.
The Index Date shall be the date of the first date meeting the following conditions.
Date of prescription of oral GC 20 mg/day or more or date of first prescription of steroid pulses in the same month in which a disease code 7100007 excluding suspected cases was given.
Not applicable
250
1st name | Nobuo |
Middle name | |
Last name | Nishijima |
CHUGAI PHARMACEUTICAL CO.,LTD.
Medical Affairs Div.
103-8324
1-1 Nihonbashi-Muromachi 2-Chome, Chuo-Ku Tokyo
03-3281-6611
cma-clinicaltrial@chugai-pharm.co.jp
1st name | Tsutomu |
Middle name | |
Last name | Urakawa |
CHUGAI PHARMACEUTICAL CO.,LTD.
Medical Affairs Div.
103-8324
1-1 Nihonbashi-Muromachi 2-Chome, Chuo-Ku Tokyo
03-3281-6611
cma-clinicaltrial@chugai-pharm.co.jp
CHUGAI PHARMACEUTICAL CO.,LTD.
Nippon Shinyaku Co., Ltd.
Self-funding
Self funding
Non-Profit Organization MINS Institutional Review Board
1-15-14, Dogenzaka, Shibuya, Tokyo, Japan
03-6416-1868
npo-mins@j-irb.com
NO
2023 | Year | 12 | Month | 14 | Day |
Unpublished
No longer recruiting
2023 | Year | 10 | Month | 02 | Day |
2023 | Year | 10 | Month | 18 | Day |
2023 | Year | 12 | Month | 18 | Day |
2024 | Year | 06 | Month | 30 | Day |
[Organization for analysis]
INTAGE Healthcare Inc.
[Organization providing data]
JMDC Inc.
2023 | Year | 12 | Month | 13 | Day |
2024 | Year | 12 | Month | 04 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000060587